Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities

These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.

Aurobindo Pharma receives USFDA approval for Mometasone Furoate Monohydrate nasal spray

The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million

Briefs: Aurobindo Pharma and Granules Pharmaceuticals

Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection

Aurobindo Pharma receives USFDA approval for Darunavir Tablets

Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23

Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma

The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete

Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals

Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company